Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks
Open Access
- 5 September 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 16 (1), 139
- https://doi.org/10.1186/s12916-018-1130-7
Abstract
There is increasing interest in estimating the broader benefits of public health interventions beyond those captured in traditional cost-utility analyses. Cost-benefit analysis (CBA) in principle offers a way to capture such benefits, but a wide variety of methods have been used to monetise benefits in CBAs. To understand the implications of different CBA approaches for capturing and monetising benefits and their potential impact on public health decision-making, we conducted a CBA of human papillomavirus (HPV) vaccination in the United Kingdom using eight methods for monetising health and economic benefits, valuing productivity loss using either (1) the human capital or (2) the friction cost method, including the value of unpaid work in (3) human capital or (4) friction cost approaches, (5) adjusting for hard-to-fill vacancies in the labour market, (6) using the value of a statistical life, (7) monetising quality-adjusted life years and (8) including both productivity losses and monetised quality-adjusted life years. A previously described transmission dynamic model was used to project the impact of vaccination on cervical cancer outcomes. Probabilistic sensitivity analysis was conducted to capture uncertainty in epidemiologic and economic parameters. Total benefits of vaccination varied by more than 20-fold (£0.6–12.4 billion) across the approaches. The threshold vaccine cost (maximum vaccine cost at which HPV vaccination has a benefit-to-cost ratio above one) ranged from £69 (95% CI £56–£84) to £1417 (£1291–£1541). Applying different approaches to monetise benefits in CBA can lead to widely varying outcomes on public health interventions such as vaccination. Use of CBA to inform priority setting in public health will require greater convergence around appropriate methodology to achieve consistency and comparability across different studies.Keywords
Funding Information
- National Institute of General Medical Sciences (U54GM088558)
This publication has 38 references indexed in Scilit:
- Introducing vaccination against serogroup B meningococcal disease: An economic and mathematical modelling study of potential impactVaccine, 2013
- Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: A systematic reviewVaccine, 2012
- Global Burden of Human Papillomavirus and Related DiseasesVaccine, 2012
- The Cost Effectiveness of Human Papillomavirus VaccinesDrugs, 2012
- QUALITY OF LIFE, TREATMENTS, AND PATIENTS' WILLINGNESS TO PAY FOR A COMPLETE REMISSION OF CERVICAL CANCER IN TAIWANHealth Economics, 2011
- Costs and financial feasibility of malaria eliminationThe Lancet, 2010
- Cost Effectiveness in Low- and Middle-Income CountriesPharmacoEconomics, 2009
- Effectiveness and Cost Effectiveness of Human Papillomavirus VaccinePharmacoEconomics, 2009
- Policy MonitorHow US Government Agencies Value Mortality Risk ReductionsReview of Environmental Economics and Policy, 2007
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995